Fath, Felix
Bengeser, Andreas
Barresi, Mathias
Binner, Priska
Schwab, Stefanie
Ray, Kausik K.
Krämer, Bernhard K.
Fraass, Uwe
März, Winfried
Funding for this research was provided by:
SYNLAB Holding Deutschland GmbH
Amgen GmbH
Article History
Received: 13 November 2020
Accepted: 27 September 2021
First Online: 14 October 2021
Competing interests
: Mr. Fath reports employment with SYNLAB Holding Germany GmbH, SYNLAB Academy. SYNLAB Academy received Grants from Amgen GmbH, during the conduct of the project FH ALERT; Grants from Akcea Therapeutics Germany GmbH, outside the submitted work. Dr. Binner, Mr. Bengeser and Mr. Barresi report employment with SYNLAB Holding Germany GmbH, outside the submitted work. Mrs. Schwab reports employment with SYNLAB MCC Human Genetics Mannheim GmbH, outside the submitted work. Dr. Krämer has nothing to disclose. Dr. Fraass is employed by Amgen GmbH and additionally holds stock, outside the submitted work. Dr. März reports grants and personal fees from AMGEN, Grants and other from SYNLAB Holding Deutschland GmbH, during the conduct of the study; Grants from Siemens Healthineers, Grants and personal fees from Aegerion Pharmaceuticals, Grants and personal fees from AMGEN, grants from Astrazeneca, Grants and personal fees from Sanofi, Grants and personal fees from Alexion Pharmaceuticals, Grants and personal fees from BASF, Grants and personal fees from Abbott Diagnostics, Grants and personal fees from Numares AG, grants and personal fees from Berlin-Chemie, other from SYNLAB Holding Deutschland GmbH, Grants and personal fees from Akcea Therapeutics, Grants from Bayer Vital GmbH , grants from bestbion dx Gmbh, grants from Boehringer Ingelheim Pharma GmbH Co KG, grants from Immundiagnostik GmbH, Grants from Merck Chemicals GmbH, Grants from MSD Sharp and Dohme GmbH, Grants and personal fees from Novartis Pharma GmbH, Grants from Olink Proteomics, outside the submitted work. Dr. Ray reports receiving investigator initiated research Grants to his institution from Amgen, Sanofi, Regeneron, MSD, Pfizer, Daiichi Sankyo and honoraria for consultancy from Amgen, Sanofi, Regeneron, MSD, Pfizer, Astra Zeneca, Lilly, Medicines Company, Kowa, IONIS, Takeda, Novo Nordisk, Boehringer Ingelheim, Esperion, Cipla, Algorithm, Abbvie, Resverlogix, Cerenis, Novartis, Akcea, Silence Therapeutics.